Adherence to antihyperglycemic medications and glucagon-like peptide 1-receptor agonists in type 2 diabetes: clinical consequences and strategies for improvement
Open accessThe DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
Adherence to antihyperglycemic medications is often suboptimal in patients with type 2 diabetes, and this can contribute to poor glycemic control, increased hospitalization, and the development of diabetic complications. Reported adherence rates to antihyperglycemics vary widely among studies, and this may be related to differences in methodology for measuring adherence, patient populations, and other factors. Poor adherence may occur regardless of the specific regimen used and whether therapy is oral or injectable, and can be especially common in chronic, asymptomatic conditions, such as type 2 diabetes. More convenient drug-administration regimens and advances in formulations and delivery devices are among strategies shown to improve adherence to antihyperglycemic therapy, especially for injectable therapy. This is exemplified by technological developments made in the drug class of glucagon-like peptide 1-receptor agonists, which are a focus of this narrative review. Dulaglutide, albiglutide, and prolonged-release exenatide have an extended duration of action and can be administered once weekly, whereas such agents as liraglutide require once-daily administration. The convenience of once-weekly versus once-daily administration is associated with better adherence in real-world studies involving this class of agent. Moreover, provision of a user-friendly delivery device has been shown to overcome initial resistance to injectable therapy among patients with type 2 diabetes. This suggests that recent innovations in drug formulation (eg, ready-to-use formulations) and delivery systems (eg, single-dose prefilled pens and hidden, ready-attached needles) may be instrumental in encouraging patient acceptance. For physicians who aim to improve their patients' adherence to antihyperglycemic medications, it is thus important to consider the patient's therapeutic experience (treatment frequency, drug formulation, delivery device). Better adherence, powered by recent technological advances in the delivery of glucagon-like peptide 1-receptor agonists, may thus lead to improved clinical outcomes in type 2 diabetes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2015) · Diabetes Care · doi:10.2337/dc14-2441 · Cited by 3,066 · cited 1×
“…to antihyperglycemic medication and is advocated by the American Diabetes Association and the European Association for the Study of Diabetes 54,55 is that of shared decision-making: where a physician and patient make health-related decisions using a consultative process that considers not…”
Medication compliance and persistence: terminology and definitions
Cramer, J. A., Roy, A., Burrell, A., Fairchild, C. J., Fuldeore, M. J., Ollendorf, D. A., & Wong, P. K. (2008) · Value in Health · doi:10.1111/j.1524-4733.2007.00213.x · Cited by 2,220 · cited 3×
“13 The definition of persistence can thus be operationalized by determining the start of treatment (or a time point during chronic therapy) to a point in time defined as the end of the observation period.”
InfluentialMedication Adherence: WHO Cares?
Brown, M. T., & Bussell, J. K. (2011) · Mayo Clinic Proceedings · doi:10.4065/mcp.2010.0575 · Cited by 1,928 · cited 4×
“Physicians can also adversely impact adherence by prescribing complex regimens 15,17,23–25 and inadequately explaining the benefits and potential adverse events of treatment, not considering lifestyle or medication-cost issues, and having poor relationships with their patients.”
InfluentialHo, P. M., Rumsfeld, J. S., Masoudi, F. A., McClure, D. L., Plomondon, M. E., Steiner, J. F., & Magid, D. J. (2006) · Archives of Internal Medicine · doi:10.1001/archinte.166.17.1836 · Cited by 1,135
A Review of Diabetes Treatment Adherence and the Association with Clinical and Economic Outcomes
Asche, C., LaFleur, J., & Conner, C. (2011) · Clinical Therapeutics · doi:10.1016/j.clinthera.2011.01.019 · Cited by 420
Determinants of Adherence to Diabetes Medications: Findings From a Large Pharmacy Claims Database
Kirkman, M. S., Rowan-Martin, M. T., Levin, R., Fonseca, V. A., Schmittdiel, J. A., Herman, W. H., & Aubert, R. E. (2015) · Diabetes Care · doi:10.2337/dc14-2098 · Cited by 388 · cited 5×
“46,47 Perhaps surprisingly, Kirkman et al 48 showed in an analysis of pharmacy-claim data for .”
InfluentialMedication Adherence in Type 2 Diabetes: The ENTRED Study 2007, a French Population-Based Study
Tiv, M., Viel, J.-F., Mauny, F., Eschwège, E., Weill, A., Fournier, C., Fagot-Campagna, A., & Penfornis, A. (2012) · PLoS ONE · doi:10.1371/journal.pone.0032412 · Cited by 245 · cited 3×
“27 The study found a significant association between poor adherence and several modifiable factors related to medical care (eg, decision-making by the patient only, poor acceptability of medical recommendations, a need for medical support).”
InfluentialSelf-citationLongitudinal effects of medication nonadherence on glycemic control
Egede, L. E., Gebregziabher, M., Echols, C., & Lynch, C. P. (2014) · Annals of Pharmacotherapy · doi:10.1177/1060028014526362 · Cited by 146
Alatorre, C., Fernández Landó, L., Yu, M., Brown, K., Montejano, L., Juneau, P., Mody, R., & Swindle, R. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12902 · Cited by 111
Buysman, E. K., Liu, F., Hammer, M., & Langer, J. (2015) · Advances in Therapy · doi:10.1007/s12325-015-0199-z · Cited by 101 · cited 2×
“38 However, because of higher pharmacy costs, total health care costs were higher for adherent and persistent patients than for those who did not display these characteristics.”
Clifford, S., Perez-Nieves, M., Skalicky, A. M., Reaney, M., & Coyne, K. S. (2014) · Current Medical Research and Opinion · doi:10.1185/03007995.2014.884491 · Cited by 99
Cassimatis, M., & Kavanagh, D. J. (2012) · Journal of Telemedicine and Telecare · doi:10.1258/jtt.2012.gth105 · Cited by 73
Hansen, R. A., Farley, J. F., Droege, M., & Maciejewski, M. L. (2010) · Clinical Therapeutics · doi:10.1016/j.clinthera.2010.07.011 · Cited by 68
Malmenäs, M., Bouchard, J. R., & Langer, J. (2013) · Clinical Therapeutics · doi:10.1016/j.clinthera.2013.03.021 · Cited by 43 · cited 1×
“The superior adherence, lower discontinuation rate, and higher persistence for dulaglutide versus once-weekly exenatide and liraglutide 66 and the superior adherence data for once-daily liraglutide versus twice-daily exenatide 61 reported here are strengthened by the real-world nature of the data.”
Cited by
GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art
Nauck, M. A., Quast, D. R., Wefers, J., & Meier, J. J. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101102 · Cited by 1,647
Antidiabetic Drugs for the Risk of Alzheimer Disease in Patients With Type 2 DM Using FAERS
Akimoto, H., Negishi, A., Oshima, S., Wakiyama, H., Okita, M., Horii, N., Inoue, N., Ohshima, S., & Kobayashi, D. (2020) · American Journal of Alzheimer's Disease & Other Dementias® · doi:10.1177/1533317519899546 · Cited by 89
Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes: Their Use and Differential Features
Lyseng-Williamson, K. A. (2019) · Clinical Drug Investigation · doi:10.1007/s40261-019-00826-0 · Cited by 87
Caruso, I., Cignarelli, A., Sorice, G. P., Natalicchio, A., Perrini, S., Laviola, L., & Giorgino, F. (2022) · Metabolites · doi:10.3390/metabo12020183 · Cited by 86
“While in randomized controlled trials patients’ adherence is actively supported, in everyday clinical practice approximately half of type 2 diabetic patients fail to reach their glycemic target, often due to lack of adherence to glucose-lowering drugs [51].”
Self-citationSwitching Between Glucagon-Like Peptide-1 Receptor Agonists: Rationale and Practical Guidance
Almandoz, J. P., Lingvay, I., Morales, J., & Campos, C. (2020) · Clinical Diabetes · doi:10.2337/cd19-0100 · Cited by 74
Metadata
- Authors
- Giorgino, F., Penfornis, A., Pechtner, V., Gentilella, R., & Corcos, A.
- Venue
- Patient Preference and Adherence
- Publisher
- Informa UK Limited
- Published
- 2018-05
- Volume
- Volume 12
- Pages
- 707-719
- ISSN
- 1177-889X (ISSN-L)
- OpenAlex
- W2801613992
- Cited by
- 68
- References
- 14
- FWCI
- 9.58
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.